# A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants

> **NCT06311656** · PHASE1 · COMPLETED · sponsor: **DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company** · enrollment: 69 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY4100511 (DC-853)
- **DRUG:** LY4100511 (DC-853)
- **DRUG:** LY4100511 (DC-853)
- **DRUG:** LY4100511 (DC-853)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06311656
- **Lead sponsor:** DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-19
- **Primary completion:** 2024-10-04
- **Final completion:** 2024-10-04
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06311656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06311656, "A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06311656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*